
News|Articles|November 1, 2002
Path still not clear for marketing generic omeprazole
Although a New York court ruled last month that the generic manufacturer KUDCO did not infringe on two AstraZeneca patents relating to the formulation of the antiulcer drug omeprazole (Prilosec), KUDCO cannot move forward because Andrx and Genpharm hold 180-day exclusive marketing rights for various strengths. The court also ruled that Andrx and Genpharm, as well as Cheminor, did infringe on the patents--so the path is not yet clear for generic omeprazole.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
2
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































